CTRI/2016/03/006739
Completed
Phase 4
A Prospective, Multicenter Clinical Study to Assess Safety, Immunogenicity and Efficacy of Ranibizumab (Intas Pharmaceuticals Limited) for the Treatment of Wet AMD (Age Related Macular Degeneration) - NA
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: H353- Degeneration of macula and posterior pole
- Sponsor
- Intas Pharmaceuticals Ltd
- Enrollment
- 126
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male or female participant with age \>\= 50 years at the time of screening
- •2\. Active primary or recurrent subfoveal lesion with CNV(choroidal neovascularization) secondary to AMD, involving the foveal center
- •3\. Have a best corrected visual acuity of 20/40 to 20/320 using Early Treatment Diabetic Retinopathy Study chart\- ETDRS (Snellen equivalent) in the study eye. (Only one eye will be assessed in the study. If both eyes are eligible, the one with the better visual acuity is selected for treatment and study unless, based on medical reasons, the investigator deemed the other eye the more appropriate candidate for treatment and study).
- •4\. Patients able to understand and voluntarily provide written informed consent before screening, following an explanation of the nature and purpose of this study.
Exclusion Criteria
- •1\.Prior treatment with any intravitreal drug, verteporfin or photodynamic therapy in the study eye and/or non study eye within past 3 months before study entry
- •2\.Extrafoveal Laser photocoagulation within 1 month before study entry in the study eye
- •3\.Prior treatment with systemic or intravitreal bevacizumab therapy within last 6 months
- •4\.Subfoveal fibrosis or atrophy in the study eye
- •5\.CNV in either of the two eye due to causes other than AMD such as histoplasmosis or pathological myopia etc
- •6\.Retinal pigment epithelial tear involving the macula in the study eye
- •7\.Any concurrent intraocular condition in the study eye that could either require medical or surgical intervention during the 6 month study period or that could contribute to a loss of best corrected visual acuity over the 6 months study period
- •8\.Active intraocular inflammation or ongoing infection in the study eye
- •9\.Vitreous hemorrhage in the study eye or history of rhegmatogenous retinal detachment or macular hole (stage 3 or 4\) in the study eye
- •10\.Any other retinal pathology i.e. CRVO, CRAO etc.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A Prospective, Multi-center Clinical Study to Establish Multi-Cancer Early Detection Platform through the Analysis of Whole Genome Sequencing of Circulating DNA in Cancer Patients and Healthy VolunteersKCT0008484Yonsei University Health System, Severance Hospital4,000
Completed
Phase 4
Clinical study for HemoRel-A® in Hemophilia A patientsHealth Condition 1: null- Hemophilia ACTRI/2018/05/013790Dr Savita Rangarajan44
Recruiting
Phase 4
A clinical study to check the safety and effectiveness of the ANTHEM CR total knee system in patients following a Total Knee ArthroplastyHealth Condition 1: Z471- Aftercare following joint replacement surgeryCTRI/2019/01/017098Smith and Nephew Orthopaedics AG
Active, not recruiting
Phase 1
Study to evaluate the effect of rivaroxaban in patients with advanced liver disease with portal vein thrombosisiver cirrhosis and portal vein thrombosisTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-003240-37-ESFundación para la Investigación Biomédica Hospital Ramón y Cajal134
Completed
Not Applicable
A multicentre, prospective clinical study analysing outcomes of shoulder arthroplasty with SMR STEMLESSosteoarthritis of the shouldercuff tear arthropathy1002321310005944NL-OMON47760AMSA50